Publications searcher The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points. Fulltext search Alphabetic A-Z Alphabetic Z-A Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada. PMID: 31159865 Journal: BMC Pharmacology & Toxicology Year: 2019 Reference: BMC Pharmacol Toxicol. 2019 Jun 3;20(1):37. doi: 10.1186/s40360-019-0302-1. Impact factor: Publication type: Paper in international publication Authors: Aznar, Maria Luisa; Brode, Sarah K; Elshal, Ahmed Said; Marras, Theodore K; Mehrabi, Mahtab et al. DOI: 10.1186/s40360-019-0302-1 Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration. PMID: 30849549 Journal: Nanomedicine-Nanotechnology Biology and Medicine Year: 2019 Reference: Nanomedicine. 2019 Jun;18:101-111. doi: 10.1016/j.nano.2019.02.014. Epub 2019 Mar 6. Impact factor: 5.57 Publication type: Paper in international publication Authors: Aguirre, J J, Esquisabel, A, Igartua, M, Gainza, E, Hernandez, R M, Gavalda, J, Pedraz, J L, Gutierrez, F B, Bachiller, D, Fleischer, A et al. DOI: 10.1016/j.nano.2019.02.014 Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration. PMID: 30849549 Journal: Nanomedicine-Nanotechnology Biology and Medicine Year: 2019 Reference: Nanomedicine. 2019 Jun;18:101-111. doi: 10.1016/j.nano.2019.02.014. Epub 2019 Mar 6. Impact factor: Publication type: Paper in international publication Authors: Aguirre, J J; Bachiller, D; Basas, J; Esquisabel, A; Fleischer, A; Gainza, E; Gainza, G; Gavalda, J; Gomis, X; Gutierrez, F B et al. DOI: 10.1016/j.nano.2019.02.014 Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. PMID: 30446802 Journal: ANNALS OF HEMATOLOGY Year: 2019 Reference: Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Impact factor: 2.85 Publication type: Paper in international publication Authors: Claudiani, Simone, Garcia-Gutierrez, Valentin, Milojkovic, Dragana, Hernandez-Boluda, Juan Carlos, Ramirez, Maria Jose, Romero, Esperanza, Romo, Andres, Rosell, Ana, Saavedra, Silvanna Saavedra, Sebrango, Ana et al. DOI: 10.1007/s00277-018-3507-2 Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. PMID: 30446802 Journal: ANNALS OF HEMATOLOGY Year: 2019 Reference: Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Impact factor: Publication type: Paper in international publication Authors: Amustio Diez, Elena; Boque, Concepcion; Carrascosa, Guiomar Bautista; Casado-Montero, Luis Felipe; Claudiani, Simone; De Las Heras Rodriguez, Natalia; Del Carmen Garcia Garay, Maria; Fernandez, Maria Angeles; Garcia, Abelardo Barez; Garcia-Gutierrez, Valentin et al. DOI: 10.1007/s00277-018-3507-2 Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial. PMID: 30978502 Journal: Journal of Thoracic Oncology Year: 2019 Reference: J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. Impact factor: 12.46 Publication type: Paper in international publication Authors: Schildhaus, Hans-Ulrich, Franklin, Jeremy, Sebastian, Martin, Felip, Enriqueta, Grohe, Christian, Rodriguez-Abreu, Delvys, Abdulla, Diana S Y, Bischoff, Helge, Brandts, Christian, Carcereny, Enric et al. DOI: 10.1016/j.jtho.2019.03.020 Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial. PMID: 30978502 Journal: Journal of Thoracic Oncology Year: 2019 Reference: J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9. Impact factor: Publication type: Paper in international publication Authors: Abdulla, Diana S Y; Bischoff, Helge; Brandts, Christian; Buttner, Reinhard; Carcereny, Enric; Corral, Jesus; Dingemans, Anne-Marie C; Fassunke, Jana; Felip, Enriqueta; Fischer, Rieke N et al. DOI: 10.1016/j.jtho.2019.03.020 Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. PMID: 30383184 Journal: JAMA Oncology Year: 2019 Reference: JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. Impact factor: 22.416 Publication type: Paper in international publication Authors: Mesia, Ricard, Siu, Lillian L, Even, Caroline, Delord, Jean-Pierre, Krauss, Jurgen, Saba, Nabil F, Nabell, Lisle, Ready, Neal E, Brana, Irene, Kotecki, Nuria et al. DOI: 10.1001/jamaoncol.2018.4628 Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. PMID: 30383184 Journal: JAMA Oncology Year: 2019 Reference: JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. Impact factor: Publication type: Paper in international publication Authors: Armstrong, Jon M; Bonomi, Marcelo; Brana, Irene; Daste, Amaury; Delord, Jean-Pierre; Even, Caroline; Fayette, Jerome; Gilbert, Jill; Jarkowski, Anthony; Kotecki, Nuria et al. DOI: 10.1001/jamaoncol.2018.4628 Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). PMID: 31581055 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30. Impact factor: 6.68 Publication type: Paper in international publication Authors: Hoeller, Christoph, Schadendorf, Dirk, Ascierto, Paolo A, Haanen, John, Espinosa, Enrique, Demidov, Lev, Garbe, Claus, Guida, Michele, Lorigan, Paul, Chiarion-Sileni, Vanna et al. DOI: 10.1016/j.ejca.2019.08.014 Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). PMID: 31581055 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30. Impact factor: Publication type: Paper in international publication Authors: Ascierto, Paolo A; Bafaloukos, Dimitrios; Chiarion-Sileni, Vanna; Demidov, Lev; Dummer, Reinhard; Espinosa, Enrique; Fierro, Maria Teresa; Garbe, Claus; Gogas, Helen; Grigoryeva, Elena et al. DOI: 10.1016/j.ejca.2019.08.014 Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). PMID: 31445199 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21. Impact factor: 6.68 Publication type: Paper in international publication Authors: Gutzmer, Ralf, Nathan, Paul, Ascierto, Paolo A, Haanen, John, Espinosa, Enrique, Demidov, Lev, Garbe, Claus, Guida, Michele, Lorigan, Paul, Chiarion-Sileni, Vanna et al. DOI: 10.1016/j.ejca.2019.07.010 Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). PMID: 31445199 Journal: EUROPEAN JOURNAL OF CANCER Year: 2019 Reference: Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21. Impact factor: Publication type: Paper in international publication Authors: Ascierto, Paolo A; Bafaloukos, Dimitrios; Chiarion-Sileni, Vanna; Demidov, Lev; Dummer, Reinhard; Espinosa, Enrique; Fierro, Maria Teresa; Garbe, Claus; Gogas, Helen; Grigoryeva, Elena et al. DOI: 10.1016/j.ejca.2019.07.010 Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. PMID: 31487218 Journal: JOURNAL OF CLINICAL ONCOLOGY Year: 2019 Reference: J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. Impact factor: 28.245 Publication type: Paper in international publication Authors: Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, Lopez-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J et al. DOI: 10.1200/JCO.19.00739 Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. PMID: 31487218 Journal: JOURNAL OF CLINICAL ONCOLOGY Year: 2019 Reference: J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. Impact factor: Publication type: Paper in international publication Authors: Boni, Valentina; Calvo, Emiliano; Chen, Tian; Delord, Jean-Pierre; Devlin, Michael-John; Evans, Thomas R J; Gu, Junchen; Hollebecque, Antoine; Kerger, Joseph; Li, Bin et al. DOI: 10.1200/JCO.19.00739 Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. PMID: 31285147 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Impact factor: 28.755 Publication type: Paper in international publication Authors: Rudick, Richard, Cadavid, Diego, Mellion, Michelle, Hupperts, Raymond, Edwards, Keith R, Calabresi, Peter A, Drulovic, Jelena, Giovannoni, Gavin, Hartung, Hans-Peter, Arnold, Douglas L et al. DOI: 10.1016/S1474-4422(19)30137-1 Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. PMID: 31285147 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Impact factor: Publication type: Paper in international publication Authors: Aguera Morales, Eduardo; Al Khedr, Abdullatif; Ampapa, Radek; Arnold, Douglas L; Arroyo, Rafael; Belkin, Martin; Bonek, Robert; Boyko, Alexey; Cadavid, Diego; Calabresi, Peter A et al. DOI: 10.1016/S1474-4422(19)30137-1 Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. PMID: 31492652 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Impact factor: 28.755 Publication type: Paper in international publication Authors: Cohen, Jeffrey A, Comi, Giancarlo, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdova, Eva, Cree, Bruce A C et al. DOI: 10.1016/S1474-4422(19)30238-8 Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. PMID: 31492652 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Impact factor: Publication type: Paper in international publication Authors: Arnold, Douglas L; Bar-Or, Amit; Cohen, Jeffrey A; Comi, Giancarlo; Cree, Bruce A C; Hartung, Hans-Peter; Huang, Vivian; Kappos, Ludwig; Kubala Havrdova, Eva; Minton, Neil et al. DOI: 10.1016/S1474-4422(19)30238-8 Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. PMID: 31492651 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Impact factor: 28.755 Publication type: Paper in international publication Authors: Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Ding, Ning, Cohen, Jeffrey A, Kubala Havrdova, Eva, Montalban, Xavier, Steinman, Lawrence, Comi, Giancarlo et al. DOI: 10.1016/S1474-4422(19)30239-X Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. PMID: 31492651 Journal: LANCET NEUROLOGY Year: 2019 Reference: Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3. Impact factor: Publication type: Paper in international publication Authors: Arnold, Douglas L; Bar-Or, Amit; Cohen, Jeffrey A; Comi, Giancarlo; Cree, Bruce A C; Ding, Ning; Hartung, Hans-Peter; Kappos, Ludwig; Kubala Havrdova, Eva; Minton, Neil et al. DOI: 10.1016/S1474-4422(19)30239-X Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. PMID: 31446994 Journal: LUNG CANCER Year: 2019 Reference: Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8. Impact factor: 4.599 Publication type: Paper in international publication Authors: Nosaki, Kaname, Saka, Hideo, Hosomi, Yukio, Baas, Paul, de Castro, Gilberto Jr, Reck, Martin, Wu, Yi-Long, Brahmer, Julie R, Felip, Enriqueta, Sawada, Takeshi et al. DOI: 10.1016/j.lungcan.2019.07.004 Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. PMID: 31446994 Journal: LUNG CANCER Year: 2019 Reference: Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8. Impact factor: Publication type: Paper in international publication Authors: Baas, Paul; Brahmer, Julie R; de Castro, Gilberto Jr; Felip, Enriqueta; Han, Shi Rong; Hosomi, Yukio; Kush, Debra A; Lopes, Gilberto; Noguchi, Kazuo; Nosaki, Kaname et al. DOI: 10.1016/j.lungcan.2019.07.004 Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. PMID: 30858217 Journal: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Year: 2019 Reference: Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: AAC.02280-18. doi: 10.1128/AAC.02280-18. Print 2019 May. Impact factor: 4.715 Publication type: Paper in international publication Authors: Arroyo, A, Barbero, J M, Cuadra, F, Del Arco, A, Del Toro, M D, Guio, L, Jimenez-Beatty, D, Lois, N, Martin, O, Martinez Alvarez, R M et al. DOI: 10.1128/AAC.02280-18 Pagination First page « First Previous page ‹ Previous … Page 778 Page 779 Page 780 Page 781 Current page 782 Page 783 Page 784 Page 785 Page 786 … Next page Next › Last page Last »
